HMPL-523(300mg PO QD) ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
61自己免疫性溶血性貧血1

61. 自己免疫性溶血性貧血


臨床試験数 : 146 薬物数 : 131 - (DrugBank : 59) / 標的遺伝子数 : 28 - 標的パスウェイ数 : 158
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05535933
(ClinicalTrials.gov)
September 202231/8/2022HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaA Randomized, Double-Blind, Placebo-Controlled Phase II/III Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HMPL-523 in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaWarm Antibody Autoimmune Hemolytic AnemiaDrug: HMPL-523(300mg PO QD);Drug: PlaceboHutchison Medipharma LimitedNULLNot yet recruiting18 Years75 YearsAll110Phase 2/Phase 3NULL